may, 2015

18mayallday20alldayNext Generation Protein Summit


Event Details

Delivering you the very latest breakthroughs and results from an ever expanding number of protein molecules in development and offers you the best opportunity to learn from worldrenowned academics and industry visionaries. This is the industry\’s most comprehensive conference for sharing new ideas to accelerate the discovery, engineering and development of alternative scaffolds and novel protein therapeutics to create differentiated drugs.


Complete Brochure Now Available
» Download Today!

\’Again, an extremely useful update on the next wave of targeted protein therapies, well done\’ – Fredrik Frejd, Vice President, Research, Affibody

By Attending You Will:

  • Case Studies on the successful delivery of therapeutics that cross the blood-brain barrier, immunotherapies, and difficult clinical targets
  • Profit from learnings on design, development and approval of bispecifics and multispecific proteins
  • Hear the latest data and clinical breakthroughs for scaffolds, antibody fragments, peptides, and immunotherapies

\’An all-encompassing smorgasbord to provide a really comprehensive update on what is happening in the biologics space\’ – Catherine Hutchings, Principal Scientist, Antibody Discovery, Heptares Therapeutics

Keynote Presentations

\'PeterPotent Antibody Drug Conjugates for Cancer Therapy
Peter Senter, Ph.D.
Vice President, Chemistry
Seattle Genetics

\'PaulBispecific Antibodies – Are We There Yet?
Paul J. Carter, Ph.D.
Staff Scientist and Senior Director, Antibody Engineering
Genentech, Inc.

\'AndreasNew Engineering and Application Perspectives of Scaffold Proteins
Andreas Plückthun, Ph.D.
Director, Department of Biochemistry
University of Zurich, Switzerland

\'PatrickDevelopment of Bite® Antibody Construct Blinatumomab – The First FDA-Approved Bispecific Antibody
Patrick Baeuerle
Vice President, Research; General Manager
Amgen Research GmbH, Germany

\'JamesEngineered Proteins for Signaling
Jim Wells, Ph.D.
Professor and Chair, Pharmaceutical Chemistry

\'MarkReceptor-Mediated Delivery of Bispecific Antibodies into the Primate Brain: Challenges and Safety Findings
Mark Dennis, Ph.D.
Principal Scientist, Antibody Engineering
Genentech, Inc.

\’This conference is one of the best IBC conferences I have ever attended. I like the new ideas and active discussions in the meeting\’ – Liang Tang, Principal Scientist, Bayer Healthcare


may 18 (Monday) - 20 (Wednesday)


Parc 55 Hilton

San Francisco, California